Literature DB >> 26798595

MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Thanyanan Reungwetwattana1, Sai-Hong Ignatius Ou1.   

Abstract

Entities:  

Year:  2015        PMID： 26798595      PMCID： PMC4700217          DOI： 10.3978/j.issn.2218-6751.2015.12.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  23 in total

1.  MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

Authors:  Carrie Lee; Dimitry Usenko; Garrett M Frampton; Caitlin McMahon; Siraj M Ali; Jared Weiss
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

2.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

3.  MET-Mutated NSCLC with Major Response to Crizotinib.

Authors:  Melody A Mendenhall; Jonathan W Goldman
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

4.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

5.  MET Mutation Associated with Responsiveness to Crizotinib.

Authors:  Saiama N Waqar; Daniel Morgensztern; Jennifer Sehn
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

6.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Authors:  Patrick C Ma; Ramasamy Jagadeeswaran; Simha Jagadeesh; Maria S Tretiakova; Vidya Nallasura; Edward A Fox; Mark Hansen; Erik Schaefer; Katsuhiko Naoki; Alan Lader; William Richards; David Sugarbaker; Aliya N Husain; James G Christensen; Ravi Salgia
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

7.  Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Giorgio Scagliotti; Joachim von Pawel; Silvia Novello; Rodryg Ramlau; Adolfo Favaretto; Fabrice Barlesi; Wallace Akerley; Sergey Orlov; Armando Santoro; David Spigel; Vera Hirsh; Frances A Shepherd; Lecia V Sequist; Alan Sandler; Jeffrey S Ross; Qiang Wang; Reinhard von Roemeling; Dale Shuster; Brian Schwartz
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

Review 8.  Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.

Authors:  J Jean Cui
Journal:  J Med Chem       Date:  2013-12-18       Impact factor: 7.446

9.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

10.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962
View more
  7 in total

Review 1.  Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Authors:  Niki Karachaliou; Aaron E Sosa; Miguel Angel Molina; Margarita Centelles Ruiz; Rafael Rosell
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.

Authors:  Nehad M Ayoub; Dalia R Ibrahim; Amer E Alkhalifa
Journal:  Med Oncol       Date:  2021-10-19       Impact factor: 3.064

3.  MET∆14 promotes a ligand-dependent, AKT-driven invasive growth.

Authors:  Marina Cerqua; Orsola Botti; Maddalena Arigoni; Noemi Gioelli; Guido Serini; Raffaele Calogero; Carla Boccaccio; Paolo M Comoglio; Dogus M Altintas
Journal:  Life Sci Alliance       Date:  2022-05-30

Review 4.  MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.

Authors:  Mark A Socinski; Nathan A Pennell; Kurtis D Davies
Journal:  JCO Precis Oncol       Date:  2021-04-13

5.  Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.

Authors:  Takahiko Koyama; Kahn Rhrissorrakrai; Laxmi Parida
Journal:  BMC Cancer       Date:  2019-02-01       Impact factor: 4.430

6.  Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.

Authors:  Beili Gao; Ran Zeng
Journal:  Front Med (Lausanne)       Date:  2022-01-31

7.  Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes.

Authors:  Corina N A M van den Heuvel; Arvid I Das; Tessa de Bitter; Femke Simmer; Thomas Wurdinger; Miguel Angel Molina-Vila; William P J Leenders
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.